|
 |
|
|||||||
|
|||||||||
Copyright ©ERS Journals Ltd 2005
Physiological changes during symptom recovery from moderate exacerbations of COPD
1 Dept of Medicine, Queen's University, Kingston, and 2 Ottawa Health Research Institute, University of Ottawa, Ottawa, Canada.
CORRESPONDENCE: D. O'Donnell, 102 Stuart Street, Kingston, Ontario, Canada K7L 2V6. Fax: 1 6135491459. E-mail: odonnell@post.queensu.ca
Keywords: Chronic obstructive pulmonary disease, dyspnoea, exacerbation, lung hyperinflation
Received: November 29, 2004
Accepted April 20, 2005
Acute exacerbations of chronic obstructive disease (AECOPD) are characterised by worsening dyspnoea that is variably prolonged. In this study, physiological changes during moderate AECOPD were examined and the factors associated with dyspnoea resolution over time were determined.
In total, 20 patients experiencing an AECOPD were evaluated within 72 h of initial worsening of symptoms (day 0) with pulmonary function testing, metabolic testing and symptom assessment using the dyspnoea domain of the Chronic Respiratory Disease Questionnaire (CRQ). Treatment was optimised and testing was repeated after 7, 14, 30 and 60 days.
At day 0, patients were very short of breath (CRQ-dyspnoea mean±SEM 2.4±0.3) and showed significant airflow obstruction (forced expiratory volume in one second (FEV1) 41±3% predicted) and lung hyperinflation (forced residual capacity (FRC) 164±7% pred). By day 60 CRQ-dyspnoea improved to 4.6±0.5 (some shortness of breath); FRC and residual volume decreased by 5 and 11%, respectively; inspiratory capacity (IC) and slow vital capacity increased by 18 and 17%, respectively; and FEV1 increased by 18% with no change in FEV1/FVC. Total lung capacity did not change during AECOPD, and thus, changes in IC reliably reflected changes in end-expiratory lung volume.
In conclusion, moderate acute exacerbation of chronic obstructive pulmonary disease is characterised by worsening airflow obstruction and lung hyperinflation. Improvement of dyspnoea following acute exacerbations of chronic obstructive pulmonary disease was associated with reduction in lung hyperinflation and consequent increase in expiratory flow rates.
This article has been cited by other articles:
|
|
 |
|
  P. Albert and P. M. A. Calverley Drugs (including oxygen) in severe COPD Eur. Respir. J., May 1, 2008; 31(5): 1114 - 1124. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Cazzola, W. MacNee, F. J. Martinez, K. F. Rabe, L. G. Franciosi, P. J. Barnes, V. Brusasco, P. S. Burge, P. M. A. Calverley, B. R. Celli, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers Eur. Respir. J., February 1, 2008; 31(2): 416 - 469. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. J. Martinez Pathogen-directed Therapy in Acute Exacerbations of Chronic Obstructive Pulmonary Disease Proceedings of the ATS, December 1, 2007; 4(8): 647 - 658. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Polverino, F. P. Gomez, H. Manrique, N. Soler, J. Roca, J. A. Barbera, and R. Rodriguez-Roisin Gas Exchange Response to Short-Acting beta2-Agonists in Chronic Obstructive Pulmonary Disease Severe Exacerbations Am. J. Respir. Crit. Care Med., August 15, 2007; 176(4): 350 - 355. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. R. Celli and P. J. Barnes Exacerbations of chronic obstructive pulmonary disease Eur. Respir. J., June 1, 2007; 29(6): 1224 - 1238. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Gunen, S. S. Hacievliyagil, O. Yetkin, G. Gulbas, L. C. Mutlu, and E. In The role of nebulised budesonide in the treatment of exacerbations of COPD Eur. Respir. J., April 1, 2007; 29(4): 660 - 667. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. K Johnson, M. Birch, R. Carter, J. Kinsella, and R. D Stevenson Measurement of physiological recovery from exacerbation of chronic obstructive pulmonary disease using within-breath forced oscillometry Thorax, April 1, 2007; 62(4): 299 - 306. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. M. Pinto-Plata, G. Livnat, M. Girish, H. Cabral, P. Masdin, P. Linacre, R. Dew, L. Kenney, and B. R. Celli Systemic Cytokines, Clinical and Physiological Changes in Patients Hospitalized for Exacerbation of COPD Chest, January 1, 2007; 131(1): 37 - 43. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. O'Donnell and P. Laveneziana Physiology and consequences of lung hyperinflation in COPD Eur. Respir. Rev., December 1, 2006; 15(100): 61 - 67. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. A. Calverley Exercise and dyspnoea in COPD Eur. Respir. Rev., December 1, 2006; 15(100): 72 - 79. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R Rodriguez-Roisin COPD exacerbations {middle dot} 5: Management. Thorax, June 1, 2006; 61(6): 535 - 544. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Fabbri, F. Luppi, B. Beghe, and K. F. Rabe Update in chronic obstructive pulmonary disease 2005. Am. J. Respir. Crit. Care Med., May 15, 2006; 173(10): 1056 - 1065. [Full Text] [PDF]
|
|
|
|
|
|
J. A. Wedzicha and T. Wilkinson Impact of Chronic Obstructive Pulmonary Disease Exacerbations on Patients and Payers Proceedings of the ATS, May 1, 2006; 3(3): 218 - 221. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S Scott, P Walker, and P M A Calverley COPD exacerbations {middle dot} 4: Prevention Thorax, May 1, 2006; 61(5): 440 - 447. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D E O'Donnell and C M Parker COPD exacerbations {middle dot} 3: Pathophysiology. Thorax, April 1, 2006; 61(4): 354 - 361. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |